Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 31, 2018
Galderma Announces the Results of Phase 2b Study of Nemolizumab in Patients with Atopic Dermatitis
TOKYO, October 31, 2018 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Galderma, Nestlé Skin Health’s Medical Solutions Business issued a press release regarding the results of phase 2b study of nemolizumab (CIM331) created by Chugai in patients with moderate-to-severe atopic dermatitis to investigate the efficacy and safety of nemolizumab.
Please refer to the link below for details of the press release:
Galderma Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis
https://www.nestleskinhealth.com/news/galderma-announces-positive-results-phase-2b-study-nemolizumab-patients-moderate-severe-atopic
[Reference]
Press release issued on July 21, 2016:
Chugai and Galderma Announce Global License Agreement for Nemolizumab (CIM331), Novel Biologic for Skin Diseases
https://www.chugai-pharm.co.jp/english/news/detail/20160721083000.html
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
